Drug shortages
HHS proposes policies to prevent drug shortages. Find out how AHA is collaborating with the private sector to mitigate supply chain vulnerabilities.
The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965).
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription drug shortages that threaten the quality of patient care and increase hospital and health system costs.
AHA provides feedback on the Food and Drug Administration’s request for comments on the public meeting, “Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions.
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists, and Institute for Safe Medication Practices today released recommendations emerging from a recent drug shortages summit.
The National Academies of Sciences, Engineering and Medicine has released a report summarizing its Sept. 5-6 workshop on medical drug shortages during disasters and opportunities to better predict, prevent and respond to shortages.
The Food and Drug Administration will hold a public meeting Nov. 27 to receive stakeholder input on the underlying systemic causes of drug shortages and recommendations to mitigate them.
Several hospitals and health systems today officially established Civica Rx – a new not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving medications.
The Drug Enforcement Administration today issued its proposed 2019 aggregate production quotas for certain controlled substances, which the agency said would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent.